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To provide an update on recent revisions to Evaluation of Genomic Applications in Practice and
Prevention (EGAPP) methods designed to improve efficiency, and an assessment of the
implications of whole genome sequencing for evidence-based recommendation development.
Improvements to the EGAPP approach include automated searches for horizon scanning, a
quantitative ranking process for topic prioritization, and the development of a staged evidence
review and evaluation process. The staged process entails (i) triaging tests with minimal evidence
of clinical validity, (ii) using and updating existing reviews, (iii) evaluating clinical validity prior
to analytic validity or clinical utility, (iv) using decision modeling to assess potential clinical
utility when direct evidence is not available. EGAPP experience to date suggests the following
approaches will be critical for the development of evidence based recommendations in the whole
genome sequencing era: (i) use of triage approaches and frameworks to improve efficiency, (ii)
development of evidence thresholds that consider the value of further research, (iii) incorporation
of patient preferences, and (iv) engagement of diverse stakeholders. The rapid advances in
genomics present a significant challenge to traditional evidence based medicine, but also an
opportunity for innovative approaches to recommendation development.
Keywords
evidence-based medicine/methods; evidence-based medicine/standards; genetics; genomics/
methods; genomics/standards; medical/methods
INTRODUCTION
In 2004, the Office of Public Health Genomics (OPHG) of the Centers for Disease Control
and Prevention (CDC) recognized a critical need for providing guidance to health-care
providers and patients on the appropriate use of the genomic tests that were rapidly being
introduced in clinical practice and marketed directly to consumers. In response to this need,
the OPHG launched Evaluation of Genomic Applications in Practice and Prevention
(EGAPP), the first federal, evidence-based initiative to specifically address genomic testing.
The independent EGAPP Working Group was established for the purpose of adapting
existing evidence review methods to the systematic evaluation of genomic tests and to link
scientific evidence to recommendations for the clinical use of genomic tests, thereby
addressing the challenges posed by complex and rapidly emerging genomic applications.
The significant challenges in developing evidence-based reviews and recommendations for
genomic tests include: (i) uncertainty and difficulty in establishing clinical validity, (ii) lack
of direct evidence of clinical utility (i.e., lack of evidence directly connecting the use of a
test to the clinical outcome), (iii) the rapid development and marketing of a large number of
tests, and (iv) the lack of a robust regulatory infrastructure for genetic testing, hampering the
dissemination of such testing into clinical practice. Further, systematic reviews of tests are
complex because there are many steps between the ordering of the test and the outcome with
respect to the patient’s health.1 In addition, reviews of genomic tests require that many
outcomes be considered, given that the results often have implications for family members
and society as well. Lastly, there is limited consensus among stakeholders about the types of
evidence needed, outcomes to be assessed, and thresholds to be set before recommending
genomic tests.2
In order to address some of these challenges, EGAPP developed a set of methods based on
the evaluation of analytical validity, clinical validity, clinical utility, and, to some extent, the
ethical, legal, and social implications (ELSI) of each test (the “ACCE” framework).3,4 This
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approach uses systematic, transparent, and evidence-based methods for identifying and
evaluating evidence and developing recommendations, and is based, to a large extent, on the
approach of the United States Preventive Services Task Force (USPSTF).5 To date, EGAPP
has commissioned 10 reviews and developed recommendations for 8 genomic tests (two
tests had “recommendations for” routine use, one had a “recommendation against,” and for
five tests there was “insufficient evidence” to make a recommendation).
Despite the successful development of these recommendations, EGAPP has encountered
several challenges in the process: (i) significant time and resources were dedicated to
evaluating tests that proved to have no clinical validity or implausible clinical utility, (ii)
there was no formal framework for evaluating indirect evidence of clinical utility, and (iii)
the overall process was time-consuming in the context of the paucity of direct evidence of
clinical utility and the growing number of tests being made available. These challenges
almost certainly will be exacerbated by the recent significant increases in genome
sequencing capabilities.
The objective of this report is to provide an update on the EGAPP methodological
procedures that were developed using an iterative consensus development process with the
primary goal of improving efficiency without sacrificing quality. We also assess the
implications of the era of whole-genome sequencing for developing evidence-based
guidelines. These findings will facilitate the use of pragmatic, evidence-based processes by
various organizations that evaluate genomic tests or develop genomic testing procedures.
SELECTION OF GENOMIC TESTS FOR SYSTEMATIC REVIEW
Identification of tests
The methods previously developed by EGAPP to identify potential topics for review include
systematic searches and nomination by EGAPP members, the EGAPP stakeholders group,
steering committee, external consultants, and the OPHG staff. In addition, outside
stakeholders (individuals, professional organizations, industry, test developers, and
scientists) may submit topics online for consideration.3,6
Automated procedures were added in 2009, when the OPHG staff began regular, systematic
horizon scanning. The staff members use Google Alerts with defined queries to search Web
pages, newspaper articles, and blogs. Such searches have been able to identify two to three
new tests each week.7 Search terms are intentionally broad (e.g., “gene expression,” “cancer
test,” “genomics test”) so as to capture all relevant items. Although these searches are highly
sensitive, they often lack specificity because of redundancy of test names, duplicate reports,
reports of translational research on tests not yet available in clinical practice, and
information that is incomplete and difficult to verify.7 Therefore, although EGAPP has had
some success with automated searches, assessment of the results ultimately require
significant amounts of time to be spent by skilled persons.
Prioritization and selection of tests
The EGAPP topics subcommittee has developed a structured process to describe and
categorize potential topics, and then rate them according to the perceived health burden
associated with them as well as practical issues such as availability of the test, relevance of
the review to health-care providers and consumers, and the potential clinical or public health
impact of the review (Table 1). Potential topics are scored independently by at least two
members of the topics subcommittee, and ranked by priority. This approach provides a
consistent and transparent process for developing a quantitative ranking of potential topics.
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However, quantitative ranking is but one component of the process of topic selection.
EGAPP also seeks to select topics that challenge, test, and enhance its methodologies, and
expand the range of categories of disease states and assays to which its methods are applied.
Importantly, EGAPP avoids duplicating the efforts of other independent groups that issue
evidence-based recommendations.3,6 As a consequence, although the selection of topics is
guided by the quantitative ranking, it is also informed by other important contextual factors.
Summaries are prepared to describe the disorder, the test, the clinical scenario, and a range
of other issues (e.g., relevant drugs in the case of pharmacogenomics topics, existing
guidelines or recommendations, relevance to target audiences, and potential impact on
medical practice). These summaries are presented to the entire working group, which votes
on the final selection of the topics for which reviews will be commissioned and
recommendations written.
REVIEW OF THE EVIDENCE AND DEVELOPMENT OF
RECOMMENDATIONS
The EGAPP review model
EGAPP reviews of genomic tests were originally based on traditional review methods
shared by many other groups conducting evidence-based reviews.3 EGAPP’s first step is to
develop an analytic framework that makes explicit the series of steps linking a genomic test
to management decisions and treatment options which, in turn, are linked to important health
outcomes. The intermediate steps are addressed by key questions that are formulated to
correlate with the analytic framework. The key questions are then answered using evidence
from a variety of sources. This creates a chain of evidence, and provides indirect evidence
where direct evidence is lacking, for drawing conclusions about the effect of the test on
health outcomes.3,8 Along with the analytic framework, EGAPP reviews refer to a
conceptual framework termed “ACCE”: Analytic validity, Clinical validity, Clinical utility,
and Ethical, legal and social issues, which has been described in detail previously.3,4,9
Development of a staged review process
The early systematic evidence reviews commissioned by EGAPP took up significant time
and resources, often only to find that there was little evidence to evaluate. Some tests lacked
clinical validity, and others had no plausible clinical utility (e.g., no effective medical
management that could be based on the outcome of testing). In order to address this issue,
EGAPP piloted a targeted review process that was intended to be just as rigorous, but
shorter, less expensive, and more timely than a full systematic review, in topics involving
insufficient evidence.3 Instead of full-scale evidence reviews, the USPSTF uses targeted
reviews for recommendation updates.5 The purpose of the EGAPP targeted review process
was to pursue the elements of the ACCE framework that were of most importance, although
no formal approach was specified for this undertaking. EGAPP subsequently initiated two
targeted reviews. However, in the process of collecting sufficient evidence and carrying out
sufficient analysis of the data required to support a recommendation, EGAPP found that all
the targeted reviews became as comprehensive and time-consuming as the nontargeted ones.
The complexity of the reviews, the lack of a defined process, and the need for coordination
between the external review groups and EGAPP contributed to this situation.
The EGAPP methods subcommittee therefore embarked on developing a “staged review
process” to improve efficiency. The USPSTF employs a staged review process in an ad hoc
manner “when critical gaps in the chain of evidence become apparent during the full
evidence review of a new topic”5; however, our experience indicated that such an approach
was difficult in the absence of predefined criteria specifying when to initiate a staged
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review, and without a high level of flexibility in respect of resource allocation and
contractual terms for the research group undertaking the evidence review. The EGAPP
methods subcommittee therefore sought to develop a defined process adapted to the
particular evidence challenges involved in reviewing genomic tests.
The stages developed by EGAPP involve (i) quickly checking the quantity of evidence early
in the process, (ii) using existing reviews, (iii) evaluating clinical validity before evaluating
analytic validity and clinical utility, and (iv) using decision (scenario) modeling (Figure 1).
This approach, to be described in detail in this article, does not obviate the need to perform
the major task of assessing the certainty of the evidence and the magnitude of the effect (or
net health benefit) when the decision to proceed with a recommendation is made.
Quantity of evidence and “not reviewable” status—In order to quickly remove
topics from consideration early in the selection process, EGAPP methods and topics
subcommittees focus on clinical validity as the first criterion. Although a variety of other
criteria could be used to identify tests for early exclusion, we found that identifying clear
and efficient thresholds for clinical actionability, clinical utility, and conflicting/negative
reports of clinical validity (e.g., quality of evidence) was challenging. An OPHG staff
person spends ~1 day searching for evidence on a single topic using Google, PubMed, and
the Human Genome Epidemiology Network (HuGENet).10 If fewer than two published or
unpublished studies are found, the search process and findings are presented to the topics
subcommittee. If the subcommittee agrees with the findings, the test is then considered by
the full EGAPP Working Group for the status of “not currently reviewable.” Because the
requirement for a minimum of two studies is somewhat arbitrary, in some cases the
subcommittee may decide that a single, large, and well-conducted study is sufficient to
remove a test from the “not currently reviewable” category.
Using existing reviews—EGAPP limits searches for existing reviews to high-yield
databases to identify the most relevant, recent, high-quality reviews most efficiently.11 In
addition, EGAPP members and OPHG staff utilize personal contacts within the evidence
review and genomic evaluation fields (including the Agency for Healthcare Research and
Quality) to identify reviews that are planned or under way. EGAPP seeks collaboration with
investigators who are either planning or in the process of conducting a review; for instance,
EGAPP members offer to serve on expert review panels. Once existing reviews are
identified, they are assessed for their relevance to the proposed EGAPP review and for their
quality.
The relevance of an existing review is determined on the basis of its subject matter,
methods, and timeliness. The subject matter must correspond to EGAPP’s interest in the
indication, patient population, clinical setting, and outcomes examined, and/or to the
individual key questions. The methods used by the existing review must be transparent and
appropriate. Timeliness is assessed on the basis of the dates of the existing review’s
literature search. If the existing review is outdated, EGAPP considers whether it could be
updated easily. If the existing review only partly addresses the key questions, EGAPP
considers what additional work would be necessary. Because the key questions in existing
systematic reviews often do not correspond exactly with those of the recommendation, the
suitability of using existing systematic reviews is a judgment call that must be made on a
case-by-case basis.
The staff and EGAPP members assigned to the topic assess the quality of relevant existing
systematic reviews, using established instruments. Four instruments used for assessing
quality or completeness of reporting of systematic reviews are compared in Table 2. The
propagation of errors can be limited by selecting only reviews that are judged to be of high
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quality.11,12 Although the quality of reporting does not automatically assure the rigor of the
review process or the validity of its conclusions, this approach is nevertheless preferable to
unstructured assessment of published systematic reviews.
Sufficiently relevant and high-quality reviews can become the basis for an EGAPP
recommendation. In the case of existing reviews that address only certain key questions in
the chain of evidence, the existing review would be incorporated into the relevant aspect of
the EGAPP review.11 However, an existing review of a portion of the evidence chain may
be sufficient for scenario modeling and formal decision analysis or for EGAPP to make a
recommendation using the staged review process.
For example, EGAPP used existing systematic reviews for its recommendation on testing for
KRAS and downstream signaling gene mutations to determine whether anti-EGFR therapy
would be effective for patients with metastatic colon cancer. A systematic review13 by the
Blue Cross and Blue Shield Association Technology Evaluation Center addressed the early
evidence for KRAS gene testing. A second review by the Tufts Center for Clinical Evidence
Synthesis, under contract with the Agency for Healthcare Research and Quality, updated the
data.14 A third systematic review evaluated downstream signaling gene mutation testing
(i.e., BRAF, AKT, NRAS, PTEN, and PIK3CA).15 The data from these three reviews were
used collectively to generate the EGAPP recommendation.
Evaluation of clinical validity—When EGAPP proceeds with a new review, clinical
validity is typically assessed before analytic validity or clinical utility. The rationale for this
approach is pragmatic. There tends to be more published evidence directed toward
establishing clinical validity (rather than analytic validity or clinical utility) of biomarkers,
and an assessment of the presence or absence of such evidence is often a straightforward
process. By contrast, data on the analytic validity of tests are typically not published or even
publishable, unless novel issues are raised by an assay, and are seldom otherwise available
unless the test has been approved or cleared by the US Food and Drug Administration. As
for the clinical validity of a test, it is dependent on elements of analytic validity, and
therefore findings of at least adequate clinical validity carry implications relevant to
assessment of analytic validity, particularly if testing was conducted in laboratories that
would be used in clinical practice. Establishing clinical utility would likewise carry
important implications for both analytic and clinical validity. However, direct evidence of
clinical utility is rarely available for molecular genetic testing or for other laboratory tests.
Additionally, the process of establishing the existence of a favorable balance of benefits
versus harms, indicating a positive impact on health outcomes, can be a challenging and
resource-intensive endeavor. Therefore, without sufficient evidence to support the clinical
validity of a test, there is little need to proceed with other aspects of the ACCE evaluation
model. Despite the fact that the initial focus of the process is on the evaluation of clinical
validity, assessment of analytic validity and clinical utility are required steps if sufficient
evidence of clinical validity is identified. This is discussed in greater detail in the following
section.
Simple decision modeling: scenario modeling—The original EGAPP methods
paper discussed the use of decision models in two contexts: (i) the use of simple decision
models to aid in assessing net benefit under the “translating evidence into
recommendations” section and (ii) the use of modeling to inform nuancing of the
“insufficient” recommendation under the “recommendation language” section. We present
here a revised and more explicit description of the use of decision models. The key revisions
include: (i) the use of simple decision models to identify “fatal flaws” during the evidence
review process— after evaluation of clinical validity but before formal evaluation of clinical
utility—and (ii) the use of formal decision models as an inherent component of the evidence
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review process (as needed), rather than as a contextual issue for recommendation language
development.
Formal and explicit depiction of the use and outcomes of a genomic test—an extension of
the analytic framework—may help refine the evaluation of the test.17 A decision tree, used
in the field of decision analysis, describes multiple alternative decisions and outcomes, and
the process of specifying one helps to structure the problem.18 Whereas an analytic
framework provides a structure for the key questions that should be evaluated, a decision
tree describes the specific steps in the use and outcomes of a test. For example, an analytic
framework may include clinical benefits and clinical harms associated with testing, and a
decision tree would depict specific outcomes as well as links between surrogate outcomes
and clinical end points, and the first three elements of the ACCE framework (analytic
validity, clinical validity, and clinical utility) can be captured in a straightforward manner.
The development of a decision tree is essentially the creation of a detailed schematic;
quantitative analysis (scenario modeling) is a subsequent step, as described in the following.
The development of a decision tree provides a method to carry out a quantitative assessment
of the general likelihood that the genomic test will provide clinical utility. This is done by
conducting a series of “what-if “ scenarios. In scenario modeling—essentially a simplified
approach to decision analysis—initial quantitative estimates (not necessarily based on
systematic evidence reviews) are assigned to key questions; these, in combination with the
structure provided by the decision tree, are used to predict the potential outcomes of using
the test. The likely key parameters include the prevalence rates of genomic variants, the
strength of association between variant and outcome, and the effectiveness of intervention(s)
based on the genomic test result. Other parameters that could be varied include analytic
validity and patient/provider decisions. Outcomes can be assessed under three scenarios:
base-case, best-case, and worst-case estimates. An important (and challenging) requirement
of scenario modeling in the EGAPP context is that the process should be time-efficient. The
goal is to identify tests that fall short of a low threshold for plausibility of clinical utility
because of factors such as modest specificity for a low-frequency variant or the lack of a
clinical intervention with known benefits. Although it may be possible to identify such “fatal
flaws” before evaluation of clinical validity and issue a “recommendation against” use, a
formal assessment of clinical validity provides valuable information for stakeholders
(particularly researchers) despite the lack of plausible clinical utility. Tests that, in the
judgment of the EGAPP Working Group, have potential clinical utility as per scenario
modeling will proceed to a full evidence review.
Formal decision modeling as a component of a full evidence review—If a test
has supporting evidence of clinical validity and plausible clinical utility in scenario
modeling, it proceeds to a full evidence review, using the traditional ACCE structure. At this
point, the full evidence review needs to assess only analytic validity and clinical utility. As a
complement to the full ACCE evidence review, EGAPP prefers the use of formal decision
analysis in the commonly encountered situation in which there is no direct evidence of
clinical utility—thereby enabling a formal, although modeled, evaluation of the comparative
outcomes of various testing (or no testing) strategies.19,20 There are no objective criteria for
judging when a particular decision analysis will provide valuable insights; the judgment will
be highly dependent on the specific test and the available evidence. The decision to include
a formal decision analysis as a component of the evidence review is made jointly by EGAPP
and the researchers conducting the review. It is important to note that decision analysis is
not a substitute for evidence, but rather synthesizes both direct and indirect evidence and
seeks to reduce the accompanying uncertainty.
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A formal decision analysis differs from scenario modeling in that it (i) uses the best
available evidence derived from the full evidence review, (ii) includes in-depth evaluation of
uncertainty using formal sensitivity analysis methods, and (iii) tests key assumptions.21
Recognized standards for conducting decision analyses should be followed.18,22
Stakeholders are supportive of decision models of genomic testing that are rigorous,
transparent, and updated as new evidence becomes available, yet simple to understand and
to communicate.2 The goal, therefore, should not be the unattainable one of attaining a
correct or error-free model. Rather, the goal should be to arrive at a model that is good
enough to reasonably answer the question that drove its creation.23
Formal decision analysis may include quality-adjusted life-years as a summary measure of
overall benefit, capturing effects on both life expectancy and quality of life. However, some
stakeholders report that quality-adjusted life-years can be difficult to interpret within a
recommendation development process.2 Therefore, EGAPP seeks modeled estimates of
clinical events (both benefits and harms) and life expectancy in addition to quality-adjusted
life-years, as appropriate. Ultimately, EGAPP’s criteria for conducting specific decision
analyses and using the results to develop recommendations will be case dependent; however,
the rationale for these should be spelled out explicitly in the evidence review and
recommendation statement.
Future development of methods: integration with existing approaches
Methodological issues related to process efficiency, particularly to ease of use for end-users
(e.g., evidence review groups and other recommendation groups), should be considered in
future development work. Some of these are described in the following.
Analytic framework and key questions—With experience, EGAPP has learned that
ACCE components do not always map exactly to the analytic framework model, and that
evidence review groups prefer to define the question of interest using the PICO framework:
Patient population, Intervention, Comparison, and Outcome.24 Integration of the analytic
and ACCE frameworks with the specific PICO factors to be assessed during the review
process will promote broader usability of EGAPP evidence review methods. Because
genomic test indications address different clinical scenarios (risk assessment, prognosis,
pharmacogenomics, screening, and diagnosis), it may be useful to develop separate standard
analytic frameworks for reviews according to the category of their expected clinical
application.
Evaluating the quality of evidence and the strength of recommendations—
EGAPP’s assessment of the quality of evidence relies heavily on study design, potentially
conflating assessment of the quality of evidence with the strength of, or the ability to make,
recommendations. The GRADE system for assessing the quality of the evidence and for
determining the strength of a recommendation focuses on the overall strength of evidence
for each (type of) outcome.25 GRADE initially assigns to valid observational studies of
diagnostic accuracy (clinical validity) a “high quality” rating, and then goes on to identify
factors that might lower the rating (Table 3).26 Adopting some aspects of GRADE or using
GRADE concepts to refine EGAPP methods may make the latter more comparable to other
methods in current use.
Recommendation categories and terminology—In developing evidence-based
recommendations, EGAPP uses terminology consistent with that of the USPSTF. EGAPP’s
recommendations are phrased as “recommend for,” “recommend against,” or “insufficient
evidence.” The recommendation of insufficient evidence is further qualified as “neutral,”
“discouraging,” or “encouraging.” The USPSTF also frequently concludes that “evidence is
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insufficient to recommend for or against…” clinical preventive services. This conclusion is
often frustrating to clinicians, for whom the recommendations were developed.8
GRADE recommendations are phrased as “for using an intervention” or “against using an
intervention.” The recommendations are further qualified according to their strength,
classified as either strong or weak. In addition to the balance of positive and negative
outcomes and the quality of evidence, the strength of the recommendation is affected by the
variation in values and preferences, the health-care resource utilization and costs of the
intervention, and the ethical, social, and legal implications of using the test.27 The
consideration of such factors would necessitate their systematic evaluation, and their
integration into the process of developing the recommendation statement is likely to prove
challenging. To date, EGAPP has not made a decision to update recommendation language
to harmonize more closely with that of GRADE. In addition to a consideration of the
conventions of other groups, revisions to the terminology used in recommendations would
need to consider whether and how the preferences of end-users of the recommendation
should be incorporated.
IMPLICATIONS OF THE ERA OF WHOLE-GENOME SEQUENCING FOR
EVIDENCE-BASED GUIDELINES
The advent of relatively inexpensive whole-exome and whole-genome sequencing
technologies will bring a paradigm shift in the availability of genomic information for many
patients. Although information will be available on millions of possible variants, the number
of clinically relevant variants will be smaller, in the range of hundreds to thousands. Yet
even this amount of information will make it untenable to undertake lengthy evaluations of
appropriate clinical use on a variant-by-variant basis. The evolution of evidence-based
approaches such as those used by EGAPP will be essential for providing reliable evaluations
for clinicians and patients. Such approaches will need to encompass methods already
developed by EGAPP and by others for assessing the clinical utility of using multiple
variants for disease risk prediction.28 Here, based on our experience, we outline some of the
implications of the era of whole-genome sequencing for improving the efficiency of a
robust, evidence-based recommendation process.
Frameworks and updating
Researchers and clinicians have begun developing frameworks for addressing the challenges
presented by genome sequencing. The EGAPP Working Group is currently attempting to
detail specific considerations related to returning test results from whole-genome
sequencing. Current proposals for frameworks to categorize or triage whole-genome results
have focused on expert-driven placement of results into individual “bins” to provide
guidance for return of results incidental to the original testing indication.29 The evidence
evaluation process for these approaches needs further development, with due consideration
of the multitude of possible attributes of each result. The amount of information generated
from whole-genome sequencing is intimidating, and will be further complicated by the need
to update recommendations. The National Guideline Clearinghouse30 requires updating
within 5 years. Given the scope of information derived from genome sequencing and the
pace of scientific research, updating will be needed frequently, resulting in important
resource implications.
Evidence thresholds and value of future research
A critical issue that will need to be addressed is the relative evidence threshold for
recommending return of results to a patient versus recommending clinical actions based on
the result. Solutions to this issue may require modification of traditional recommendation
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categories. In addition, assessment of the cost and value of future research using formal
value of information analyses or frameworks may help refine decisions about “insufficient
evidence” or “weak” recommendations.31
Patient preferences and personal utility
Evidence-based reviews have traditionally focused on patient health outcomes (i.e.,
morbidity and mortality) or their surrogates (e.g., physiologic measures). However, the
results of genomic tests may also have subjective outcomes that are important to patients.32
Given the increasing focus on patient-centered care and the abundance of genomic
information that will become available from whole-genome sequencing and related
technologies, it will become important to provide methods for assessing patient preferences
with respect to the possible outcomes of genetic and genomic testing. Such preferences and
their variations need to reflect the attitudes of individuals. It has been suggested that
guidelines should state whether the recommendations are subject to patient preferences.33
Given that patient preferences are very relevant to personalized clinical application of
genomic information, additional research and method development in this area are needed.
Evaluating the role of these patient-centric factors in the recommendation development
process will be a critical and necessary step for implementing genomic technologies in a
demonstrably evidence-based manner.
Stakeholder engagement
Genome sequencing will probably involve a greater number of stakeholders than traditional
single-gene or single-variant testing because of the multitude of incidental findings and the
resources needed to effectively manage and implement this information in clinical care.
Given the increasing level of interest in stakeholder engagement as a part of the comparative
effectiveness research (CER) movement, it is likely that approaches developed in that field
may be useful for groups developing evidence-based recommendations, particularly given
the potentially conflicting objectives of guidelines that are expert informed and yet
independent.34 However, comparative effectiveness research and stakeholder engagement
have focused on the prioritization, design, and dissemination of research, not on guidelines
and recommendations. The National Institute of Health and Clinical Excellence has
accumulated substantial experience with stakeholder engagement through appraisal
committees that generate policy recommendations for the National Health Service. In
addition, for many years now, the Food and Drug Administration has implemented a
deliberate, resource-intensive approach to including patients and consumers in its advisory
committees. Also, the Agency for Healthcare Research and Quality has invested substantial
resources in refining its approach to stakeholder engagement in producing systematic
reviews.35 EGAPP and other guideline-development groups can look to these and related
experiences to guide future efforts at stakeholder engagement in the program.
SUMMARY
EGAPP has gained significant experience in selecting topics, using existing reviews,
commissioning reviews, and making recommendations about genomic tests during its 7
years of existence. With the number of available genomic (and sequencing) tests increasing
rapidly, evidence-based approaches to assess these genomic tests will need to evolve. The
evaluation process must be efficient, pragmatic, and credible. The EGAPP experience and
findings can provide guidance to organizations using genomic tests or developing
procedures for evaluating genomic testing in this rapidly evolving field.
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Figure 1. Steps in staged evidence review and evaluation process
AV, analytic validity; CU, clinical utility; C V, clinical validity; ER, evidence review.
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Table 2
Established instruments for assessing quality of systematic reviews
Criterion field









Identification and purpose Identify the report as a
systematic review,
metaanalysis, or both. Provide
a structured summary.
Describe the rationale for the
review.
Provide an explicit statement
being addressed.
A priori protocol Was an a priori
design provided?
Is the topic well defined? Indicate if a review protocol
exists.
Search strategy Were the search
methods
reported?
Present full electronic search
strategy for at least
one database.







Was the search for papers
thorough?
Describe all information
sources and dates in the
search.
Inclusion criteria Were the inclusion
criteria
reported?






Were the criteria for inclusion
of studies clearly described?
Specify eligibility criteria.








Show study selection flow
diagram.
Selection bias Was selection bias
avoided?
Were the criteria for inclusion








Describe method of data
extraction.
List and define all variables
for which data were
sought.
Missing information Was missing information
sought from
the original investigators?










For each study, present
characteristics for which
data were extracted.








Was study quality assessed by
blinded
or independent reviewers?
Describe methods used for
assessing risk of bias
of individual studies.
Present data on risk of bias of
each study and,
if available, any outcome-level
assessment.
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Criterion field











Do the included studies seem
to
indicate similar effects?















































firmly on the quality of the
evidence
presented?
Summarize the main findings
including the
strength of evidence for each
main outcome.
Discuss limitations at study
level, outcome level,
and review level.




Specify any assessment of risk
of bias that may
affect the cumulative
evidence. Present results of
any assessment of risk of bias
across studies.
Context and implications Provide a general
interpretation of results in the








Describe sources of funding
and role of funders.
Quality of review What was the overall
scientific quality of the
overview?
PRISMA provides guidelines for reporting systematic reviews, rather than explicitly evaluating quality.













Veenstra et al. Page 18
Table 3
GRADE quality assessment criteria for diagnostic accuracy studies (clinical validity)
underlying study design
Valid diagnostic accuracy studies (cross-sectional or cohort) in patients with diagnostic uncertainty and direct comparison of test results with an
appropriate reference standard are initially rated as high-quality evidence. These studies are rare, however.
Factors that may decrease the quality of evidence
  ↓ Limitations in design or execution of the study (risk of bias)
  ↓ Indirectness (comparison or the population, new test, comparison test, and outcomes)
  ↓ Inconsistency in study results
  ↓ Imprecise results
  ↓ High probability of reporting bias
If any of the factors warranting downgrading is present, consider whether the limitations are serious (downgrade by one level) or very serious
(downgrade by two levels).
Reprinted from the GRADE Diagnosis Workshop package and with permission from HolgerSchünemann and Jan Brożek.
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